<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875378</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY19070395</org_study_id>
    <secondary_id>R01HD099139</secondary_id>
    <nct_id>NCT03875378</nct_id>
  </id_info>
  <brief_title>Transdermal Estrogen in Women With Anorexia Nervosa</brief_title>
  <official_title>Transdermal Estrogen for the Treatment of Bone Loss in Women With Anorexia Nervosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pouneh K. Fazeli, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, placebo-controlled study investigating the use of physiologic, transdermal
      estrogen for low bone mass in adult women with anorexia nervosa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anorexia nervosa is a prevalent psychiatric with a lifetime prevalence of up to 2.2%. Among
      the many medical co-morbidities associated with anorexia nervosa, the most common is
      significant bone loss, which can persist despite weight recovery. Nearly 90% of women with
      anorexia nervosa have osteopenia and this low bone mass is associated with an increased
      fracture risk. Nearly 30% of women with anorexia nervosa report a history of a fracture and a
      prospective study demonstrated a 7-fold increased risk of fracture in women with anorexia
      nervosa compared to age-matched controls. Because anorexia nervosa is a chronic disease that
      can persist despite psychiatric and nutritional counseling, the bone loss and increased
      fracture risk can persist and lead to lifelong morbidity. Therefore, finding a treatment for
      bone loss associated with anorexia nervosa is of critical importance.

      This 18-month randomized, placebo-controlled study will investigate in women (ages 20 to 45
      years old) with anorexia nervosa whether treatment with transdermal estrogen replacement will
      increase bone mineral density (BMD).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">August 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bone mineral density at 18 months</measure>
    <time_frame>Baseline, 18 months</time_frame>
    <description>Change in lumbar spine bone mineral density at 18 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in bone mineral density at hip at 18 months</measure>
    <time_frame>Baseline, 18 months</time_frame>
    <description>Change in total hip bone mineral density at 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone mineral density at femoral neck at 18 months</measure>
    <time_frame>Baseline, 18 months</time_frame>
    <description>Change in femoral neck bone mineral density at 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in parameters of bone microarchitecture at 18 months</measure>
    <time_frame>Baseline, 18 months</time_frame>
    <description>Change in microarchitectural parameters as measured by high-resolution peripheral quantitative CT at 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in estimated bone strength at 18 months</measure>
    <time_frame>Baseline, 18 months</time_frame>
    <description>Change in estimated bone strength as assessed by finite element analysis at 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vertebral fractures at 18 months</measure>
    <time_frame>Baseline, 18 months</time_frame>
    <description>Change in vertebral fractures as assessed by vertebral fracture assessment at 18 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Anorexia Nervosa</condition>
  <arm_group>
    <arm_group_label>Transdermal estrogen/progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) patch applied weekly for 18 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo patch applied weekly for 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal estrogen</intervention_name>
    <description>Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) weekly patch</description>
    <arm_group_label>Transdermal estrogen/progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo weekly patch</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female

          2. 20-45 years of age

          3. DSM-5 psychiatric criteria for anorexia nervosa

          4. &lt;85% of ideal body weight as defined by the 1983 Metropolitan Life Insurance Height
             and Weight Tables

          5. Amenorrhea

          6. T-score of &lt; -1.0 at spine or hip

        Exclusion Criteria:

          1. Diseases known to affect bone metabolism, including untreated thyroid dysfunction,
             vitamin D deficiency, Cushing's syndrome, diabetes mellitus or renal insufficiency
             (eGFR &lt; 60)

          2. Personal history of venous or arterial clot

          3. History of stroke or myocardial infarction

          4. History of migraine headaches

          5. History of hypercoagulable disorder

          6. Personal history or history of a first-degree relative with breast cancer

          7. History of hereditary angioedema

          8. Any medication known to affect bone metabolism, including systemic glucocorticoids
             within three months of the baseline visit, depot medroxyprogesterone within 6 months
             of the baseline visit, oral bisphosphonates within one year of the baseline visit or
             IV bisphosphonates within three years of the baseline visit

          9. Bone fracture within the prior 12 months

         10. Serum potassium &lt; 3.0 meq/L, serum ALT &gt; 3 times the upper limit of normal or
             Hemoglobin &lt; 10 g/dL

         11. Fasting serum triglyceride level &gt; 150 mg/dL

         12. Pregnant or breastfeeding (or desiring pregnancy within the next 18 months)

         13. Active substance abuse

         14. Elevated PTH level

         15. 25-OH vitamin D level &lt; 20 ng/mL

         16. Low phosphorus level
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pouneh Fazeli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pouneh Fazeli, MD</last_name>
    <phone>412-648-9761</phone>
    <email>pkfazeli@pitt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shari Reynolds</last_name>
    <phone>412-383-0570</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pittsburgh School of Medicine</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pouneh K Fazeli, MD</last_name>
      <phone>412-648-9761</phone>
      <email>pkfazeli@pitt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shari Reynolds</last_name>
      <phone>412-383-0570</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Pouneh K. Fazeli, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Bone mineral density</keyword>
  <keyword>Estrogen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The final dataset will include self-reported demographic and behavioral data from interviews with the subjects, laboratory data from blood specimens provided and radiologic images of subjects with anorexia nervosa. Because anorexia nervosa is a psychiatric disease and we will be collecting identifying information, even though the final dataset will be stripped of identifiers prior to release for sharing, we believe that the information disclosed by the subjects should be protected in the most stringent way possible in order to prevent possible identification of subjects. Thus, we will make the data and associated documentation available to users only under a data-sharing agreement that provides for: 1) a commitment to using the data only for research purposes and not to identify any individual participant; 2) a commitment to securing the data using appropriate computer technology; and 3) a commitment to destroying or returning the data after analyses are completed.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>12 months after publication and no pre-specified end date.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

